FST-100 in the Treatment of Acute Adenoviral Conjunctivitis
NCT ID: NCT01470664
Last Updated: 2021-06-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
176 participants
INTERVENTIONAL
2012-12-17
2014-05-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
FST-100 in the Treatment of Acute Viral Conjunctivitis
NCT01461954
FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis
NCT00941486
Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis
NCT01532336
Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis
NCT03230058
Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo
NCT02998554
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FST-100
FST-100
0.1% dexamethasone and 0.6% polyvinylpyrrolidone iodine (PVP-Iodine)
FST-100 (Component #1)
FST-100 (Component #1)
0.6% PVP-Iodine ophthalmic solution alone
FST-100 Vehicle
FST-100 Vehicle
FST-100 Vehicle
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FST-100
0.1% dexamethasone and 0.6% polyvinylpyrrolidone iodine (PVP-Iodine)
FST-100 (Component #1)
0.6% PVP-Iodine ophthalmic solution alone
FST-100 Vehicle
FST-100 Vehicle
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shire
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ora, Inc.
Andover, Massachusetts, United States
Ora, Inc.
Noida, , India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FST100-AVC-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.